Clinical Development at MorphoSys

Hitting the home stretch

With the development of the antibody MOR208, MorphoSys has reached the most advanced development stage as a biotechpharmaceutical company. Originally, we started out as explorers and service providers. We have identified thousands of antibodies for our pharma partners, the most promising of which are in development. Today, MOR208 is the first antibody from our proprietary pipeline that we intend to develop to market approval on our own account. MOR208 is being investigated for the treatment of blood cancer, such as diffuse large B cell lymphoma (DLBCL), an aggressive cancer of the lymphatic system. With this, MOR208 gives hope to patients by addressing a high unmet medical need. For those DLBCL patients who do not respond to standard therapies, current treatment options are very ­limited. We carry out multiple clinical studies and, by now, can see the home stretch. In October 2017, the U.S. Food and Drug Administration (FDA) granted breakthrough therapy designation for MOR208 in combination with lenalidomide. As we intend to apply for FDA approval by the end of 2019, we have already started setting up a commercial organization in the U.S. Prospectively, the development of proprietary drug candidates up to market approval will be a central pillar of MorphoSys’s business model.

Clinical Development at MorphoSys

Hitting the home stretch

With the development of the antibody MOR208, MorphoSys has reached the most advanced development stage as a biotechpharmaceutical company. Originally, we started out as explorers and service providers. We have identified thousands of antibodies for our pharma partners, the most promising of which are in development. Today, MOR208 is the first antibody from our proprietary pipeline that we intend to develop to market approval on our own account. MOR208 is being investigated for the treatment of blood cancer, such as diffuse large B cell lymphoma (DLBCL), an aggressive cancer of the lymphatic system. With this, MOR208 gives hope to patients by addressing a high unmet medical need. For those DLBCL patients who do not respond to standard therapies, current treatment options are very ­limited. We carry out multiple clinical studies and, by now, can see the home stretch. In October 2017, the U.S. Food and Drug Administration (FDA) granted breakthrough therapy designation for MOR208 in combination with lenalidomide. As we intend to apply for FDA approval by the end of 2019, we have already started setting up a commercial organization in the U.S. Prospectively, the development of proprietary drug candidates up to market approval will be a central pillar of MorphoSys’s business model.